Indications
Ryjunea is indicated for slowing the progression of myopia in paediatric patients. Treatment may be initiated in children aged 3-14 years with a progression rate of
0.5D
or more per year and a severity of -0.5 D to -6.0 D.
Composition
- Active substance
- atropine sulfate
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ryjunea
- Active substance
- atropine sulfate
- ATC code
- S01FA01
- Group
- Sensory organs
- Therapeutic area
- Myopia
- Marketing authorisation holder
- Santen Oy